Evidence map›Paper›PMID 40979741›Full record

ArticleRespiratory medicine case reports2025

Scedosporium infection as a late complication after start of elexacaftor/tezacaftor/ivacaftor: two case reports.

P van Mourik, E C van der Hout, H D Luijk, R W Hofland, A H W Bruns, H G M Heijerman, I Bronsveld

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

P van MourikDepartment of Pulmonary Medicine, University Medical Center Utrecht, the Netherlands.
E C van der HoutDepartment of Pulmonary Medicine, University Medical Center Utrecht, the Netherlands.
H D LuijkDepartment of Pulmonary Medicine, University Medical Center Utrecht, the Netherlands.
R W HoflandDepartment of Pulmonary Medicine, University Medical Center Utrecht, the Netherlands.
A H W BrunsDepartment of Reumatology,immunology and infectious diseases, University Medical Center Utrecht, the Netherlands.
H G M HeijermanDepartment of Pulmonary Medicine, University Medical Center Utrecht, the Netherlands.
I BronsveldDepartment of Pulmonary Medicine, University Medical Center Utrecht, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Highly effective modulator treatment (HEMT) has resulted in an improved prognosis for people with cystic fibrosis (pwCF). In this case report, we present two pwCF with clinical stabilization after start of HEMT who developed complicated fungal infections after several years of clinical stability, highlighting the importance of continued careful monitoring of pwCF on HEMT and considering early antifungal treatment in this population.

Indexed as

Cystic fibrosisElexacaftor/tezacaftor/ivacaftorScedosporium

Identifiers

PMID40979741
PMCPMC12445565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.